MedTrace Logo

Assessment of DOT Spectacles in Chinese Children

NCT05562622 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 195

Last updated 2026-05-05

No results posted yet for this study

Summary

This is a randomized, controlled, evaluator-blinded, multicenter, two-arm parallel group clinical trial of 12-months duration to evaluate the continued safety and efficacy of Diffusion Optics Technology (DOT) spectacle lenses by comparing to single vision, impact-resistant spectacle lenses in reducing the progression of juvenile myopia in children of Chinese origin.

Conditions

  • Myopia
  • Juvenile Myopia

Interventions

DEVICE

Novel spectacle lens design

Use of lenses may reduce the rate of progression of juvenile myopia

DEVICE

Spectacle lenses

Use of lenses may reduce the rate of progression of juvenile myopia

Sponsors & Collaborators

  • SightGlass Vision, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
13 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-05
Primary Completion
2026-12-31
Completion
2027-12-31
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05562622 on ClinicalTrials.gov